Helicobacter pylori Treatment Guidelines

First-Line Treatment Options

The American College of Gastroenterology recommends bismuth quadruple therapy for 14 days as the preferred first-line treatment due to increasing global clarithromycin resistance and its high efficacy 1, 2
In areas with low clarithromycin resistance (<15%), triple therapy using a PPI with clarithromycin and amoxicillin (or metronidazole) for 14 days may be considered 1, 2
Concomitant (non-bismuth quadruple) therapy consisting of PPI, clarithromycin, amoxicillin, and metronidazole for 14 days is an alternative first-line option 2

High-dose PPI (twice daily) significantly increases eradication efficacy by 6-10% compared to standard doses by reducing gastric acidity and enhancing antibiotic activity 1, 2
Extending treatment duration to 14 days improves eradication success by approximately 5% compared to shorter regimens 1, 3
The use of probiotics as adjunctive treatment can help reduce side effects, particularly antibiotic-associated diarrhea, though evidence for increased eradication rates is limited 1, 2

After failure of a clarithromycin-containing therapy, either bismuth quadruple therapy (if not previously used) or levofloxacin-containing triple therapy is recommended 1, 3
Levofloxacin-based triple therapy consists of a PPI twice daily, amoxicillin 1000 mg twice daily, and levofloxacin 500 mg once daily or 250 mg twice daily, for 14 days 3

Clarithromycin resistance is the primary reason for triple therapy failure, with global resistance rates increasing from 9% in 1998 to 17.6% in 2008-2009 1, 2
In regions with clarithromycin resistance >15-20%, standard triple therapy should be abandoned due to unacceptably low eradication rates 1, 2
Bismuth is valuable because bacterial resistance to this compound is extremely rare, making bismuth quadruple therapy effective even against strains resistant to metronidazole 2

After two failed eradication attempts, antimicrobial susceptibility testing should guide further treatment whenever possible 1, 2
Rifabutin-based triple therapy (PPI, amoxicillin, rifabutin) can be considered as a rescue option after multiple treatment failures 2

Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation 1, 3
Serology should not be used to confirm eradication as antibodies may persist long after successful treatment 1

Inadequate PPI dosing significantly reduces H. pylori treatment efficacy; always use high-dose (twice daily) PPI 1, 2
Avoid repeating antibiotics to which the patient has been previously exposed, especially clarithromycin and levofloxacin, to maximize the probability of successful eradication 2
In patients allergic to penicillin, amoxicillin can be replaced with tetracycline 3
In children, fluoroquinolones and tetracyclines should not be used, limiting treatment options 4